Sutter Health and AstraZeneca form Research Collaboration to Transform Care for Diabetes and other Cardiometabolic Conditions

Posted on May 5, 2015 in Uncategorized

AstraZeneca and not-for-profit Sutter Health today announced the start of a research and innovation collaboration. The organizations will team up over the next three years to design, prototype and pilot innovative approaches to improve the lives of cardiometabolic patients by creating a more personalized, health care experience through physician and patient partnership.

Cardiometabolic care focuses on the treatment and management of diseases such as diabetes, hypertension and high cholesterol and common, co-occurring serious health complications such as heart attack, stroke, limb loss, blindness and even death. Through this collaboration, researchers will explore how to re-engineer the delivery of cardiometabolic care by improving access to and understanding of electronic health record data, testing new care models and experimenting with leading-edge technologies.

“Diabetes, high blood pressure and poorly controlled cholesterol can have an enormous impact on a person’s quality of life and the cost of health care,” said Greg Keenan, vice president of Medical Affairs and U.S. head medical officer for AstraZeneca. “Sutter Health and AstraZeneca will bring together unique expertise and experiences to improve the lives of patients. Through this innovative research collaboration with Sutter Health, we hope to improve the future of cardiometabolic care and translate solutions into programs that health systems nationwide could implement.”

More than 29 million people in the United States—or 9.3 percent of the population—have diabetes, for example, estimates the Centers for Disease Control and Prevention. Adults with diabetes have a 50 percent higher risk of death than those without the disease, and the medical costs for people with diabetes are twice as high as those without.  Improvements in cardiometabolic healthcare can potentially improve the health of people with diabetes, reduce complications of the disease and lower overall healthcare costs.

“We have unique opportunities today to dramatically improve the patient experience and outcomes through the novel use of new technologies and the application of advanced ways of using data,” said Walter “Buzz” Stewart, Ph.D., MPH, chief research officer for Sutter Health. “Innovation through the use of digital health solutions can and should give patients more control and ways to improve health and to work more closely with their providers to live healthier and more productive lives.”

Through this work, researchers hope to better understand existing gaps in cardiometabolic care and create forward-looking technologies and treatments that can help speed diagnosis and improve patients’ long-term quality of life.

Work will focus in several areas.

  • Making data meaningful: Researchers will pull key data from across the Sutter Health network into a comprehensive, electronic system and conduct novel, essential analytical steps to continually identify gaps in care; recognize and monitor patient needs; and translate these insights into guideline-based care recommendations.
  • Personalizing care: Researchers will design, develop, and implement new tools to help patients and providers work together on care options personalized to a patient’s needs and then develop innovative care approaches for use outside the traditional face-to-face clinic visit.
  • Ongoing learning: By tracking the impact of work, researchers will continually grow and evolve their efforts

Posted by on May 5, 2015 in Uncategorized | Comments Off on Sutter Health and AstraZeneca form Research Collaboration to Transform Care for Diabetes and other Cardiometabolic Conditions